Please login to the form below

Not currently logged in
Email:
Password:

Sanofi wins EU approval for new diabetes combination Suliqua

European Commission licenses the once-daily version of Lantus and Lyxumia
Sanofi

Sanofi's combination therapy Suliqua has been granted European marketing approval for the treatment of adults with type 2 diabetes.

The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is not sufficient.

Approval of the once-daily injection was based on two phase III studies - LixiLan-O and LixiLan-L - which showed Suliqua to be statistically superior in reducing blood sugar levels in comparison with both Lyxumia and Lantus.

Dr Elias Zerhouni, president of global R&D at Sanofi, said: “Suliqua is an innovative new combination therapy that has the potential to address significant unmet needs for people living with type 2 diabetes in Europe.

“The approval of Suliqua represents the successful culmination of a concerted effort by Sanofi scientists to bring two injectable treatments together in a single and precisely titratable dose.

“Sanofi has a long history of elevating care for people with diabetes, and we believe Suliqua will make it easier for patients with inadequately controlled diabetes to reach their treatment goals.”

The long-acting basal insulin and GLP-1 agonist is already on the market in the US as Soliqua, having been approved by the FDA in November last year on the same day as rival therapy Xultophy, Novo Nordisk's insulin degludec and liraglutide combination.

In the EU, however, Xultophy has the edge as it received regulatory approval in 2014 in Europe, where it is marketed as IDegLira.

Both companies are vying for market share in the sector, but analysts have predicted Xultophy will take the lead with sales of $1.2bn by 2021 in comparison with the $550m forecast for Suliqua.

Article by
Rebecca Clifford

18th January 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics